- Home
- QNCX
as 12-20-2024 3:41pm EST
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 92.3M | IPO Year: | 2019 |
| Target Price: | $9.50 | AVG Volume (30 days): | 280.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $2.45 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quince Therapeutics Inc. News
QNCX Breaking Stock News: Dive into QNCX Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Quince Therapeutics Files Mixed Securities Shelf; Shares Rise After Hours
Simply Wall St.
25 days ago
Spotlight On US Penny Stocks For November 2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/19/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/18/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/15/2024
Business Wire
a month ago
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/13/2024
Business Wire
a month ago
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Compare QNCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNCX Quince Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.